Clinical Trials Browser

Recruiting × INDUSTRY × taletrectinib × Clear all

NCT07154706 2026-02-11

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07008287 2025-07-22

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Carcinoma, Non-Small-Cell Lung